Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

Phase 3

Terminated

Conditions: Osteoarthritis

Interventions: Other: Placebo
Biological: Tanezumab

First Posted Date: 2009-08-18

Last Posted Date: 2021-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT00960804

Locations: 🇺🇸
Jem Research, LLC, Atlantis, Florida, United States
🇺🇸
Medical Specialists of the Palm Beaches, Atlantis, Florida, United States
🇺🇸
Miami Research Associates, South Miami, Florida, United States

and more 15 locations

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: CP-690,550
Drug: Placebo

First Posted Date: 2009-08-17

Last Posted Date: 2018-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 399

Registration Number: NCT00960440

Locations: 🇨🇳
Pfizer Investigational Site, Kaohsiung, Taiwan

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Advanced Breast Cancer (Parts 1 and 2)
Advanced Pancreatic Cancer (Part 1)
Advanced Colorectal Cancer (Part 1)
Advanced Cholangiocarcinoma (Part 1)
Advanced Glioblastoma Multiforme (Part 1)

Interventions: Drug: Bosutinib
Drug: Capecitabine

First Posted Date: 2009-08-17

Last Posted Date: 2013-02-22

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT00959946

Locations: 🇪🇸
Pfizer Investigational Site, Madrid, Spain

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04447943
Drug: Placebo

First Posted Date: 2009-08-17

Last Posted Date: 2009-12-07

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT00959803

Locations: 🇺🇸
Pfizer Investigational Site, Glendale, California, United States

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimer Disease

Interventions: Biological: ACC-001 (10 mcg) + QS-21
Biological: ACC-001+ QS21 (3mcg)
Biological: ACC-001+QS-21 (30mcg)

First Posted Date: 2009-08-17

Last Posted Date: 2016-04-01

Lead Sponsor: Pfizer

Target Recruit Count: 160

Registration Number: NCT00960531

Locations: 🇺🇸
Banner Boswell Medical Center, Sun City, Arizona, United States
🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 22 locations

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Phase 1

Completed

Conditions: Obesity
Overweight
Healthy

Interventions: Drug: PF-04620110
Drug: Placebo

First Posted Date: 2009-08-14

Last Posted Date: 2010-06-07

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT00959426

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Other: QS-21
Biological: ACC-001

First Posted Date: 2009-08-14

Last Posted Date: 2016-01-01

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT00959192

Locations: 🇯🇵
Kitasato University East Hospital, Kanagawa, Japan
🇯🇵
Ibaraki Prefectural Central Hospital, Ibaraki, Japan
🇯🇵
Meitetsu Hospital, Aichi, Japan

and more 6 locations

A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-04455242

First Posted Date: 2009-08-11

Last Posted Date: 2010-01-07

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00956956

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Biological: ACC-001(30µg) + QS21
Biological: ACC-001(3µg) + QS21
Biological: ACC-001(10µg) + QS21

First Posted Date: 2009-08-10

Last Posted Date: 2021-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 160

Registration Number: NCT00955409

Locations: 🇩🇪
Klinikum der Albert-Ludwigs-Universitaet Freiburg, Freiburg, Germany
🇫🇷
Groupe Hospitalier Pitie-Salpetriere, Paris, France
🇩🇪
Universitatsklinikum und Poliklinik der Uni Bonn, Bonn, Germany

and more 14 locations

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: dalteparin

First Posted Date: 2009-08-06

Last Posted Date: 2019-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 38

Registration Number: NCT00952380

Locations: 🇸🇮
Lekarna, Univerzitetni klinicni center Ljubljana, Ljubljana, Slovenia
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Investigational Drug Service Tampa General Hospital, Tampa, Florida, United States

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy